Summary
Edwards Lifesciences Corporation (EW) has filed an 8-K report detailing the completion of the sale of its Edwards LifeStent peripheral vascular product line on January 11, 2008. The transaction, agreed upon in December 2007, was with C.R. Bard, Inc. and Angiomed GMBH & Co. Medizintechnik KG. This divestiture is significant for investors as it involves a substantial cash component and potential future payments tied to regulatory and manufacturing milestones.
Key Highlights
- 1Completion of the sale of the Edwards LifeStent peripheral vascular product line on January 11, 2008.
- 2The sale was conducted through an Asset Purchase Agreement with C.R. Bard, Inc. and Angiomed GMBH & Co. Medizintechnik KG.
- 3Edwards received an initial cash payment of $74 million upon closing.
- 4An additional $65 million in cash is contingent upon achieving specific milestones, including U.S. regulatory approval for a superficial femoral artery indication and successful transfer of manufacturing.
- 5Edwards will provide transition services for up to two and a half years post-closing.
- 6The filing includes unaudited pro forma consolidated financial statements (balance sheet as of Sept 30, 2007, and statements of operations for the nine months ended Sept 30, 2007, and the year ended Dec 31, 2006) to reflect the impact of this divestiture.
Frequently Asked Questions
The main event reported is the completion of the sale of Edwards Lifesciences' Edwards LifeStent peripheral vascular product line to C.R. Bard, Inc. and Angiomed GMBH & Co. Medizintechnik KG, which occurred on January 11, 2008.
Edwards received an initial cash payment of $74 million. An additional $65 million in cash is due upon the achievement of certain milestones, specifically the receipt of U.S. regulatory approval for the LifeStent products for a superficial femoral artery indication and the transfer of manufacturing.
Yes, Edwards Lifesciences will provide transition services for the product line for a period of up to two and a half years following the closing of the sale.
The filing includes unaudited pro forma consolidated condensed financial statements. This includes a balance sheet as of September 30, 2007, and statements of operations for the nine months ended September 30, 2007, and the full year ended December 31, 2006. These statements are presented to give investors an idea of the company's financial position and performance as if the divestiture had already occurred.